Genoray Co. Ltd (122310) - Net Assets
Based on the latest financial reports, Genoray Co. Ltd (122310) has net assets worth ₩77.26 Billion KRW (≈ $52.36 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩125.67 Billion ≈ $85.17 Million USD) and total liabilities (₩48.41 Billion ≈ $32.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Genoray Co. Ltd (122310) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩77.26 Billion |
| % of Total Assets | 61.48% |
| Annual Growth Rate | 25.21% |
| 5-Year Change | 29.11% |
| 10-Year Change | N/A |
| Growth Volatility | 27.98 |
Genoray Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Genoray Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Genoray Co. Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Genoray Co. Ltd (2015–2024)
The table below shows the annual net assets of Genoray Co. Ltd from 2015 to 2024. For live valuation and market cap data, see 122310 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩85.89 Billion ≈ $58.21 Million |
-10.09% |
| 2023-12-31 | ₩95.53 Billion ≈ $64.74 Million |
+8.61% |
| 2022-12-31 | ₩87.96 Billion ≈ $59.61 Million |
+11.60% |
| 2021-12-31 | ₩78.82 Billion ≈ $53.41 Million |
+18.47% |
| 2020-12-31 | ₩66.53 Billion ≈ $45.08 Million |
+11.65% |
| 2019-12-31 | ₩59.59 Billion ≈ $40.38 Million |
+32.49% |
| 2018-12-31 | ₩44.97 Billion ≈ $30.48 Million |
+85.09% |
| 2017-12-31 | ₩24.30 Billion ≈ $16.47 Million |
+64.16% |
| 2016-12-31 | ₩14.80 Billion ≈ $10.03 Million |
+30.36% |
| 2015-12-31 | ₩11.35 Billion ≈ $7.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genoray Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1058.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩73.12 Billion | 85.13% |
| Common Stock | ₩7.28 Billion | 8.47% |
| Other Components | ₩5.50 Billion | 6.40% |
| Total Equity | ₩85.89 Billion | 100.00% |
Genoray Co. Ltd Competitors by Market Cap
The table below lists competitors of Genoray Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Covalon Technologies Ltd.
V:COV
|
$38.48 Million |
|
Jinli Group Holdings Ltd
TW:8429
|
$38.51 Million |
|
Ascent Solar Technologies, Inc. Common Stock
NASDAQ:ASTI
|
$38.51 Million |
|
Kafein Yazilim
IS:KFEIN
|
$38.53 Million |
|
Corem Property Group AB (publ)
ST:CORE-A
|
$38.44 Million |
|
Mentice AB
ST:MNTC
|
$38.44 Million |
|
Caprice Resources Ltd
AU:CRS
|
$38.43 Million |
|
Ihuman Inc
NYSE:IH
|
$38.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genoray Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 95,345,885,360 to 85,891,030,560, a change of -9,454,854,800 (-9.9%).
- Net loss of 1,797,494,940 reduced equity.
- Dividend payments of 2,185,077,280 reduced retained earnings.
- Share repurchases of 5,931,749,760 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-1.80 Billion | -2.09% |
| Dividends Paid | ₩2.19 Billion | -2.54% |
| Share Repurchases | ₩5.93 Billion | -6.91% |
| Other Changes | ₩459.47 Million | +0.53% |
| Total Change | ₩- | -9.92% |
Book Value vs Market Value Analysis
This analysis compares Genoray Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.68x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.89x to 0.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1599.47 | ₩4620.00 | x |
| 2017-12-31 | ₩2278.09 | ₩4620.00 | x |
| 2018-12-31 | ₩3588.72 | ₩4620.00 | x |
| 2019-12-31 | ₩4123.52 | ₩4620.00 | x |
| 2020-12-31 | ₩4654.22 | ₩4620.00 | x |
| 2021-12-31 | ₩5514.22 | ₩4620.00 | x |
| 2022-12-31 | ₩6253.53 | ₩4620.00 | x |
| 2023-12-31 | ₩6981.60 | ₩4620.00 | x |
| 2024-12-31 | ₩6768.59 | ₩4620.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genoray Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.68%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.44x
- Recent ROE (-2.09%) is below the historical average (16.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 17.59% | 6.26% | 1.12x | 2.51x | ₩861.87 Million |
| 2016 | 21.79% | 8.42% | 1.15x | 2.26x | ₩1.74 Billion |
| 2017 | 21.28% | 11.62% | 1.18x | 1.55x | ₩2.74 Billion |
| 2018 | 21.06% | 16.83% | 0.96x | 1.30x | ₩4.97 Billion |
| 2019 | 22.22% | 20.34% | 0.83x | 1.32x | ₩7.28 Billion |
| 2020 | 15.29% | 16.49% | 0.72x | 1.29x | ₩3.52 Billion |
| 2021 | 18.17% | 19.28% | 0.75x | 1.26x | ₩6.44 Billion |
| 2022 | 15.80% | 16.83% | 0.78x | 1.21x | ₩5.10 Billion |
| 2023 | 13.10% | 12.75% | 0.79x | 1.30x | ₩2.95 Billion |
| 2024 | -2.09% | -1.68% | 0.87x | 1.44x | ₩-10.39 Billion |
Industry Comparison
This section compares Genoray Co. Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $32,852,820,809
- Average return on equity (ROE) among peers: -70.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genoray Co. Ltd (122310) | ₩77.26 Billion | 17.59% | 0.63x | $38.45 Million |
| NSN Co. Ltd (031860) | $59.75 Billion | -53.11% | 0.11x | $8.50 Million |
| JOONGANG DNM Co.Ltd (051980) | $31.75 Billion | -26.44% | 0.25x | $144.40 Million |
| GeneMatrix Inc (109820) | $11.06 Billion | -13.29% | 0.60x | $27.26 Million |
| Green Cross Lab Cell Corporation (144510) | $48.10 Billion | 4.84% | 0.13x | $241.86 Million |
| Optipharm.CO.LTD (153710) | $29.01 Billion | -7.05% | 0.42x | $51.60 Million |
| Cytogen Inc (217330) | $475.51 Million | -451.97% | 9.64x | $92.24 Million |
| Gencurix Inc (229000) | $30.99 Billion | -111.87% | 0.78x | $25.56 Million |
| P&K Skin Research Center Co. Ltd (347740) | $15.96 Billion | 24.33% | 0.11x | $48.83 Million |
| Access Bio Inc (950130) | $68.58 Billion | 3.55% | 0.15x | $125.38 Million |
About Genoray Co. Ltd
Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It offers C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services. The company also exports its products to approximately 80 countries worldwide. Genoray Co., Ltd. was founded in… Read more